Show simple item record

dc.contributor.authorMeyer, Ingmar Sören
dc.contributor.authorGoetzke, Carl Christoph
dc.contributor.authorKespohl, Meike
dc.contributor.authorSauter, Martina
dc.contributor.authorHeuser, Arnd
dc.contributor.authorEckstein, Volker
dc.contributor.authorVornlocher, Hans-Peter
dc.contributor.authorAnderson, Daniel Griffith
dc.contributor.authorHaas, Jan
dc.contributor.authorMeder, Benjamin
dc.contributor.authorKatus, Hugo Albert
dc.contributor.authorKlingel, Karin
dc.contributor.authorBeling, Antje
dc.contributor.authorLeuschner, Florian
dc.date.accessioned2019-09-04T17:53:22Z
dc.date.available2019-09-04T17:53:22Z
dc.date.issued2018-10
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/1721.1/122038
dc.description.abstractMyocarditis is an inflammatory disease of the heart muscle most commonly caused by viral infection and often maintained by autoimmunity. Virus-induced tissue damage triggers chemokine production and, subsequently, immune cell infiltration with pro-inflammatory and pro-fibrotic cytokine production follows. In patients, the overall inflammatory burden determines the disease outcome. Following the aim to define specific molecules that drive both immunopathology and/or autoimmunity in inflammatory heart disease, here we report on increased expression of colony stimulating factor 1 (CSF-1) in patients with myocarditis. CSF-1 controls monocytes originating from hematopoietic stem cells and subsequent progenitor stages. Both, monocytes and macrophages are centrally involved in mediating tissue damage and fibrotic scarring in the heart. CSF-1 influences monocytes via engagement of CSF-1 receptor, and it is also produced by cells of the mononuclear phagocyte system themselves. Based on this, we sought to modulate the virus-triggered inflammatory response in an experimental model of Coxsackievirus B3-induced myocarditis by silencing the CSF-1 axis in myeloid cells using nanoparticle-encapsulated siRNA. siCSF-1 inverted virus-mediated immunopathology as reflected by lower troponin T levels, a reduction of accumulating myeloid cells in heart tissue and improved cardiac function. Importantly, pathogen control was maintained and the virus was efficiently cleared from heart tissue. Since viral heart disease triggers heart-directed autoimmunity, in a second approach we investigated the influence of CSF-1 upon manifestation of heart tissue inflammation during experimental autoimmune myocarditis (EAM). EAM was induced in Balb/c mice by immunization with a myocarditogenic myosin-heavy chain-derived peptide dissolved in complete Freund's adjuvant. siCSF-1 treatment initiated upon established disease inhibited monocyte infiltration into heart tissue and this suppressed cardiac injury as reflected by diminished cardiac fibrosis and improved cardiac function at later states. Mechanistically, we found that suppression of CSF-1 production arrested both differentiation and maturation of monocytes and their precursors in the bone marrow. In conclusion, during viral and autoimmune myocarditis silencing of the myeloid CSF-1 axis by nanoparticle-encapsulated siRNA is beneficial for preventing inflammatory tissue damage in the heart and preserving cardiac function without compromising innate immunity's critical defense mechanisms. Keywords: inflammation and immunmodulation; innate immunity, cytokines; monocytes/macrophages; RNA interference; virus; infection-immunology; myocarditisen_US
dc.language.isoen
dc.publisherFrontiers Media SAen_US
dc.relation.isversionofhttp://dx.doi.org/10.3389/fimmu.2018.02303en_US
dc.rightsCreative Commons Attribution 4.0 International licenseen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.sourceFrontiersen_US
dc.titleSilencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditisen_US
dc.typeArticleen_US
dc.identifier.citationMeyer, Ingmar Soren et al. "Silencing the CSF-1 Axis Using Nanoparticle Encapsulated siRNA Mitigates Viral and Autoimmune Myocarditis." Frontiers in Immunology 9 (October 2018): 2303 © 2018 The Authorsen_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.departmentKoch Institute for Integrative Cancer Research at MITen_US
dc.relation.journalFrontiers in Immunologyen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2019-08-09T15:02:40Z
dspace.date.submission2019-08-09T15:02:42Z
mit.journal.volume9en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record